TRICARE ends weight-loss drug coverage for TRICARE For Life and several other groups

The Defense Health Agency began enforcing existing federal rules on Aug. 31, 2025 that end TRICARE pharmacy coverage of weight-loss medications for beneficiaries who are not enrolled in TRICARE Prime, TRICARE Select, or a premium-based plan ^[1][2]. Prior authorizations that had already been approved for those beneficiaries became invalid on that date ^[1][2].

The groups affected include people with TRICARE For Life, those with direct care only access, TRICARE Plus enrollees, and foreign force members ^[1][2]. TRICARE describes the move as implementing "existing regulatory controls" so that prescription processing lines up with federal coverage requirements, not as a new policy ^[2].

Who still has coverage

Weight-loss drugs remain covered for people enrolled in TRICARE Prime or TRICARE Select, or who get those benefits through a premium-based plan: TRICARE Young Adult, TRICARE Reserve Select, TRICARE Retired Reserve, and the Continued Health Care Benefit Program ^[1]. Coverage still requires meeting TRICARE's clinical criteria, a prescription from a TRICARE network provider, and an approved prior authorization form ^[1]. Express Scripts, the TRICARE pharmacy contractor, adds that weight-loss prescriptions must be filled at a TRICARE network pharmacy ^[3].

The medications covered under those conditions include Saxenda, Wegovy, Zepbound, Qsymia, phentermine, and Contrave ^[1]. Wegovy is semaglutide; Zepbound is tirzepatide.

Diabetes coverage is unchanged. TRICARE continues to cover Trulicity, Ozempic, Mounjaro, and Victoza for type 2 diabetes for all patients with a diabetes diagnosis, regardless of health plan, when prior authorization requirements are met ^[1][2]. Ozempic, Mounjaro, and Victoza also require medical necessity forms to get the formulary copayment and coverage at a military pharmacy ^[1]. Existing cost-shares for the diabetes drugs have not changed ^[1].

Why TRICARE For Life is different

TRICARE For Life is Medicare wraparound coverage and operates under different laws than Prime or Select ^[2]. "TFL coverage of these drugs isn't authorized when obesity is the sole or major condition treated," said Edward C. Norton, chief of the Pharmacy Operations Division at the Defense Health Agency ^[2].

According to the agency, federal regulation extends coverage for obesity treatment only to Prime and Select beneficiaries when care comes from network providers, with bariatric surgery for morbid obesity as the exception ^[2]. TFL also does not mirror Medicare Part D, which may cover certain weight-loss medications for non-obesity conditions such as sleep apnea or cardiovascular risk reduction ^[2]. The rules that apply to TFL exclude medications intended to control or reduce weight regardless of co-morbid conditions, and regardless of the patient's age ^[2].

On the question of timing, the agency said Express Scripts mailed notification letters to affected beneficiaries on July 31, 2025, 30 days before the change ^[2]. TRICARE's earlier article said affected beneficiaries would get a notice in the mail "in the coming weeks" ^[1].

Why it matters for patients

For affected beneficiaries, a prescription for Wegovy, Zepbound, or another weight-loss drug filled after Aug. 31, 2025 is not paid for by TRICARE ^[2]. The agency's Q&A states plainly: "TRICARE will not cover your prescription. You can talk to your provider about other treatment options. Or you can prepare to pay for your prescription out of pocket" ^[2].

The distinction that now drives coverage is diagnosis plus plan type. A TFL beneficiary with type 2 diabetes can still get Mounjaro or Ozempic covered with prior authorization ^[2]. The same person taking Zepbound for obesity alone cannot ^[2].

The agency said affected beneficiaries "shouldn't stop taking your medication right away" and should ask a provider what is appropriate during the transition ^[2]. It pointed to nutrition counseling, lifestyle and exercise changes, and other clinically appropriate approaches as alternatives to discuss ^[1].

Several things are not spelled out in these sources: how many beneficiaries lost coverage, whether any appeal or exception process exists for the excluded groups, and what out-of-pocket prices affected patients would face.

What happens next

July 31, 2025: Express Scripts mailed notification letters to affected beneficiaries ^[2]. Aug. 31, 2025: the controls took effect and prior authorizations for obesity medications became invalid for the excluded groups ^[1][2]. TRICARE directs beneficiaries to the TRICARE Formulary Search Tool to check current coverage and required forms for a specific drug ^[1][3]. No end date or reversal has been announced in these sources.